Clinical Trials Browser

Recruiting × Neoplasms, Plasma Cell × 90 days × Clear all

Graft vs Host Disease, Neoplasms, Plasma Cell

NCT06152575 2026-04-16

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Phase 3 Recruiting

492 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06870760 2026-04-16

Pre-malignant States to Hematologic Malignancies in Firefighters

Recruiting

300 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Non-Hodgkin, Multiple Myeloma, Paraproteinemias, Neoplasms, Plasma Cell

NCT05336383 2026-04-15

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

Phase 2 Recruiting

30 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07529782 2026-04-14

Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

15 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT06066359 2026-03-11

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

Phase 1/2 Recruiting

44 enrolled

Plasma cell

Neoplasms, Plasma Cell

NCT03633955 2026-03-05

REALIZE

Phase 1 Recruiting

60 enrolled

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Neoplasms, Plasma Cell

NCT05745285 2026-02-20

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

Phase NA Recruiting

400 enrolled

LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Hematologic Neoplasms, Neoplasms, Plasma Cell

NCT05651932 2026-02-10

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1 Recruiting

125 enrolled

Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07390071 2026-02-05

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

Phase NA Recruiting

40 enrolled

LymphoidPlasma cell

Cytokine Release Syndrome, Lymphoma, Neoplasms, Plasma Cell

Clinical Trials

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Pre-malignant States to Hematologic Malignancies in Firefighters

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

REALIZE

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy